Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) started the day on Wednesday, with a price increase of 4.60% at $812.27, before settling in for the price of $776.54 at the close. Taking a more long-term approach, REGN posted a 52-week range of $476.49-$792.77.
The Healthcare sector firm’s twelve-monthly sales growth has been 15.74% for the last half of the decade. Meanwhile, its Annual Earning per share during the time was 15.74%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -5.06%. This publicly-traded company’s shares outstanding now amounts to $103.50 million, simultaneously with a float of $101.15 million. The organization now has a market capitalization sitting at $85.37 billion. At the time of writing, stock’s 50-day Moving Average stood at $723.52, while the 200-day Moving Average is $606.13.
Regeneron Pharmaceuticals, Inc (REGN) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Biotechnology Industry. Regeneron Pharmaceuticals, Inc’s current insider ownership accounts for 3.76%, in contrast to 85.47% institutional ownership. Preceding that transaction, on Nov 20 ’25, Company’s Director sold 760 for 750.00, making the whole transaction’s value amount to 570,000. This particular insider is now the holder of 1,548 in total.
Regeneron Pharmaceuticals, Inc (REGN) Earnings and Revenue Records
Regeneron Pharmaceuticals, Inc’s EPS decrease for this current 12-month fiscal period is -5.06% and is forecasted to reach 44.54 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 5.06% through the next 5 years, which can be compared against the 15.74% growth it accomplished over the previous five years trading on the market.
Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) Trading Performance Indicators
Let’s observe the current performance indicators for Regeneron Pharmaceuticals, Inc (REGN). It’s Quick Ratio in the last reported quarter now stands at 3.33. Alongside those numbers, its PE Ratio stands at $19.45, and its Beta score is 0.40. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 5.99. Similarly, its price to free cash flow for trailing twelve months is now 20.22.
In the same vein, REGN’s Diluted EPS (Earnings per Share) trailing twelve months is recorded 41.77, a figure that is expected to reach 10.68 in the next quarter, and analysts are predicting that it will be 44.54 at the market close of one year from today.
Technical Analysis of Regeneron Pharmaceuticals, Inc (REGN)
If we take a close look at the recent performances of Regeneron Pharmaceuticals, Inc (NASDAQ: REGN), its last 5-days Average volume was 0.77 million that shows plunge from its year to date volume of 0.88 million. During the previous 9 days, stock’s Stochastic %D was recorded 60.44% While, its Average True Range was 73.19.
Raw Stochastic average of Regeneron Pharmaceuticals, Inc (REGN) in the period of the previous 100 days is set at 99.33%, which indicates a major rise in contrast to 97.56% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 15.45 that was lower than 18.22 volatility it exhibited in the past 100-days period.
